An advisory panel of the U.S. Food and Drug Administration has concluded that Biomarin’s (BMRN) experimental therapy Kyndrisa or drisapersen for Duchenne muscular dystrophy did not effectively treat the condition.
Forex – financial instrument.Forex news
An advisory panel of the U.S. Food and Drug Administration has concluded that Biomarin’s (BMRN) experimental therapy Kyndrisa or drisapersen for Duchenne muscular dystrophy did not effectively treat the condition.